> Skip to content
FEATURED:
  • Public Perception of College
Sign In
  • News
  • Advice
  • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Technology
    • The Workplace
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Technology
    • The Workplace
  • Current Issue
  • Virtual Events
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Career Resources
    • Find a Job
    • Post a Job
    • Career Resources
Sign In
  • News
  • Advice
  • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Technology
    • The Workplace
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Technology
    • The Workplace
  • Current Issue
  • Virtual Events
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Career Resources
    • Find a Job
    • Post a Job
    • Career Resources
  • News
  • Advice
  • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Technology
    • The Workplace
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Technology
    • The Workplace
  • Current Issue
  • Virtual Events
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Career Resources
    • Find a Job
    • Post a Job
    • Career Resources
Sign In
ADVERTISEMENT
Research
  • Twitter
  • LinkedIn
  • Show more sharing options
Share
  • Twitter
  • LinkedIn
  • Facebook
  • Email
  • Copy Link URLCopied!
  • Print

Academic Scientists Hail Supreme Court’s Rejection of Gene Patents

By  Goldie Blumenstyk
June 13, 2013
Washington

A unanimous U.S. Supreme Court on Thursday ruled that sequences of naturally occurring genes cannot be patented, a decision hailed by academic researchers who said it “opens up the field” for genetic testing and research.

A DNA sequence, even after it is identified and isolated, is still “a product of nature and not patent eligible,” the court said in its 18-page ruling.

The ruling strikes down parts of three patents developed at the University of Utah and used by Myriad Genetics Inc. for a pricey test it sells exclusively to help predict the hereditary risk of breast and ovarian cancer. The test concerns genes known as BRCA1 and BRCA2.

We're sorry. Something went wrong.

We are unable to fully display the content of this page.

The most likely cause of this is a content blocker on your computer or network.

Please allow access to our site, and then refresh this page. You may then be asked to log in, create an account if you don't already have one, or subscribe.

If you continue to experience issues, please contact us at 202-466-1032 or help@chronicle.com

A unanimous U.S. Supreme Court on Thursday ruled that sequences of naturally occurring genes cannot be patented, a decision hailed by academic researchers who said it “opens up the field” for genetic testing and research.

A DNA sequence, even after it is identified and isolated, is still “a product of nature and not patent eligible,” the court said in its 18-page ruling.

The ruling strikes down parts of three patents developed at the University of Utah and used by Myriad Genetics Inc. for a pricey test it sells exclusively to help predict the hereditary risk of breast and ovarian cancer. The test concerns genes known as BRCA1 and BRCA2.

“Myriad did not create or alter either the genetic information encoded in the BRCA1 and BRCA2 gene or the genetic structure of the DNA,” the ruling says. “It found an important and useful gene, but groundbreaking, innovative, or even brilliant discovery does not by itself satisfy” the test for a patent, the court said, in a ruling written by Justice Clarence Thomas.

With the ruling, “the monopoly goes by the wayside,” said Harry Ostrer, a professor of pathology, genetics, and pediatrics at the Albert Einstein School of Medicine. “We can now do testing.”

ADVERTISEMENT

Dr. Ostrer, who is also director of genetic and genomic testing at the Montefiore Medical Center, was among the doctors, patients, and advocates who in 2009 sued to challenge the validity of the patents after Myriad said the genetic testing he was doing on his patients infringed the company’s patents.

The decision has big implications for researchers, Dr. Ostrer added. In the wake of the ruling, he said, “most isolated gene patents will probably fall by the wayside,” which could pave the way for more widespread and affordable testing for genes related to sudden cardiac death and many neurological disorders.

By some estimates, the U.S. Patent and Trademark Office has issued patents covering about 20 percent of the human genome, a trend that federal health officials have called a threat to the development of genetic testing and advances in personalized medicine.

‘A Rubber-Stamp Patent Office’

The case, Association for Molecular Pathology v. Myriad Genetics Inc., No. 12-398, came to the Supreme Court after a federal district court ruled against the patents and then a federal appeals court last August overturned that ruling.

The director of the National Institutes of Health, Francis S. Collins, led a round of cheering and applause when word of the court’s decision reached him while he was leading a semiannual meeting of his advisory committee, in Bethesda, Md.

ADVERTISEMENT

“What a moment,” Dr. Collins exclaimed to members of the committee, a group of 18 biomedical experts, many of them prominent university leaders, after a colleague read out the decision from her phone.

Daniel B. Ravicher, executive director of the Public Patent Foundation, which brought the suit along with the American Civil Liberties Union, called the decision “a great victory for everyone, not just for our patients and scientists” but also for anyone concerned about the right to information about their own health.

“The patent office was unashamed about granting patents on our bodies until the Supreme Court told it to stop doing that,” Mr. Ravicher said in an interview. “We have an out-of-control rubber-stamp patent office that only cares about making money.”

Welcome News

While ruling that the act of simply isolating strands of DNA was not patentable, the court made clear that inventions based on synthetically created DNA could still be patented. Dr. Ostrer said that would be welcome news to many academic investigators “and their deans,” who are eager to develop and commercialize discoveries that are “truly novel.”

University of Utah officials referred all questions about the case to Myriad. On its Facebook page, the company posted a message that said in part, “The battle that really matters isn’t in court; it’s the one against cancer.”

ADVERTISEMENT

In a similar vein, the Association of University Technology Managers said the decision would eliminate uncertainties for commercialization. The association and a biotechnology-industry trade association had called patents on isolated DNA molecules “critical to encouraging innovation” in an earlier friend-of-the-court brief in support of Myriad. “The landscape for patents has been made clearer,” said Sean Flanigan, president of the university-technology association.

Paul Basken contributed to this article.

Correction (6/17/2013, 7:11 p.m.): This article originally misstated the date of the Supreme Court’s ruling. It was Thursday, June 13, not Wednesday, June 12. The article has been updated to reflect this correction.

We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Goldie Blumenstyk
The veteran reporter Goldie Blumenstyk writes a weekly newsletter, The Edge, about the people, ideas, and trends changing higher education. Find her on Twitter @GoldieStandard. She is also the author of the bestselling book American Higher Education in Crisis? What Everyone Needs to Know.
ADVERTISEMENT
ADVERTISEMENT
  • Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Virtual Events
    • Chronicle Store
    • Chronicle Intelligence
    • Find a Job
    • Post a Job
    Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Virtual Events
    • Chronicle Store
    • Chronicle Intelligence
    • Find a Job
    • Post a Job
  • Know The Chronicle
    • About Us
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • DEI Commitment Statement
    • Accessibility Statement
    Know The Chronicle
    • About Us
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • DEI Commitment Statement
    • Accessibility Statement
  • Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Institutional Subscriptions
    • Subscription & Account FAQ
    Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Institutional Subscriptions
    • Subscription & Account FAQ
  • Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
    Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
1255 23rd Street, N.W. Washington, D.C. 20037
© 2023 The Chronicle of Higher Education
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin